Discover the full record of transactions filed by Brottem John L., General Counsel and Secretary. Director active across 1 companies, notably Outset Medical, Inc.. In total, 33 reports have been recorded. Total volume traded: €305k. The latest transaction was filed on 17 May 2022 — Cession. Regulator: SEC (Form 4). The full history is free.
25 of 33 declarations
John L. Brottem serves as General Counsel and Secretary at Outset Medical, Inc., a U.S.-listed medical technology company focused on transforming dialysis care. Public company disclosures show that he joined Outset Medical in May 2020 and became part of the senior leadership team supporting the company’s growth, governance, and compliance priorities in the U.S. market. His role is centered on corporate governance, legal oversight, securities compliance, and advising management and the board on a range of strategic and regulatory matters. Prior to joining Outset Medical, Brottem built a legal career that combined in-house leadership with experience in technology and healthcare-related businesses. He held several increasingly senior positions at Omnicell, Inc., a provider of medication management automation solutions and adherence tools, including Vice President, Legal and Deputy General Counsel; Vice President, Legal and Associate General Counsel; and Senior Director, Legal and Associate General Counsel. That progression suggests deep experience in corporate law, compliance, public-company reporting, and transactional support. Earlier in his career, he served as Corporate Counsel at Brocade Communications Systems, Inc. and Foundry Networks, Inc., both networking technology companies, and before that as an associate at Cooley Godward Kronish LLP, an international law firm. This background indicates a strong foundation in both external legal practice and strategic in-house counsel responsibilities. Brottem earned a B.A. from Occidental College and a J.D. from the University of California, Davis School of Law. In a regulated, publicly traded healthcare environment, his profile is well aligned with matters such as disclosure controls, board support, legal risk management, and the governance requirements that accompany growth in the U.S. capital markets.